Drug resistance mutation profiles of the drug-na < ve and first-line regimen-treated hiv-1-infected population of suzhou, china
文献类型：期刊论文
| 作者 | Li, Tingting1,2; Qian, Feng3; Yuan, Ting1; Xu, Weilu3; Zhu, Li3; Huang, Jinlong3; Wang, Haiyan3; Zhu, Yueping3; Wang, Yinling3; Li, Xiaohong3 |
| 刊名 | Virologica sinica
 |
| 出版日期 | 2017-08-01 |
| 卷号 | 32期号:4页码:271-279 |
| 关键词 | Hiv-1 Drug resistance mutation First-line regimen China |
| ISSN号 | 1674-0769 |
| DOI | 10.1007/s12250-017-4002-y |
| 通讯作者 | Zhu, chuanwu(zhuchw@126.com) ; Sun, binlian(sunbl@wh.iov.cn) |
| 英文摘要 | Little is known about the prevalence of drug-resistant mutations in hiv-1-positive individuals in suzhou, china. to elucidate the transmitted drug resistance (tdr) and acquired drug resistance mutation (adr) profiles, we collected blood specimens from 127 drug-na < ve and 117 first-line drug-treated hiv-1-infected individuals sampled from 2014 to 2016 in suzhou. we successfully amplified pol fragments from 100 drug-na < ve and 20 drug-treated samples. we then determined the drug-resistant mutations to protease (pr) and reverse-transcriptase (rt) inhibitors according to the stanford drug resistance database. overall, 11 and 13 individuals had transmitted (drug-na < ve group) and acquired (treated group) resistance mutations, respectively. six transmitted drug-resistant mutations were found, including two mutations (l33f and l76v) in the protease region and four (k70n/e and v179d/e) in the rt region. only l76v was a major mutation, and k70n/e and v179d/e are known to cause low-level resistance to rt inhibitors. all 13 treated participants who had major drug resistance mutations demonstrated intermediate to high resistance to efavirenz and nevirapine, and six had a treatment duration of less than three months. no major mutations to rt inhibitors were found, implying that the epidemic of transmitted resistance mutations was not significant in this area. our results suggest that more frequent virus load and drug resistance mutation tests should be conducted for individuals receiving antiretroviral treatment, especially for newly treated patients. our research provides insights into the occurrence of hiv-1 drug resistance in suzhou and will help to optimize the treatment strategy for this population. |
| WOS关键词 | RESOURCE-LIMITED SETTINGS ; HIV-INFECTED INDIVIDUALS ; ANTIRETROVIRAL TREATMENT ; LIAONING PROVINCE ; 1-INFECTED MEN ; VIRUS ; PREVALENCE ; THERAPY ; TRANSMISSION ; PERSISTENCE |
| WOS研究方向 | Virology |
| WOS类目 | Virology |
| 语种 | 英语 |
| WOS记录号 | WOS:000409488100002 |
| 出版者 | SPRINGER |
| URI标识 | http://www.irgrid.ac.cn/handle/1471x/2373376 |
| 专题 | 武汉病毒研究所 |
| 通讯作者 | Zhu, Chuanwu; Sun, Binlian |
| 作者单位 | 1.Chinese Acad Sci, Wuhan Inst Virol, Res Grp HIV Mol Epidemiol & Virol 1, State Key Lab Virol, Wuhan 430071, Hubei, Peoples R China 2.Univ Chinese Acad Sci, Beijing 100000, Peoples R China 3.Fifth Peoples Hosp Suzhou, Div HIV AIDS 1, Suzhou 215000, Peoples R China 4.Univ Western Ontario, Schulich Sch Med & Dent, Dept Microbiol & Immunol, London, ON N6A 5C1, Canada |
| 推荐引用方式 GB/T 7714 | Li, Tingting,Qian, Feng,Yuan, Ting,et al. Drug resistance mutation profiles of the drug-na < ve and first-line regimen-treated hiv-1-infected population of suzhou, china[J]. Virologica sinica,2017,32(4):271-279. |
| APA | Li, Tingting.,Qian, Feng.,Yuan, Ting.,Xu, Weilu.,Zhu, Li.,...&Sun, Binlian.(2017).Drug resistance mutation profiles of the drug-na < ve and first-line regimen-treated hiv-1-infected population of suzhou, china.Virologica sinica,32(4),271-279. |
| MLA | Li, Tingting,et al."Drug resistance mutation profiles of the drug-na < ve and first-line regimen-treated hiv-1-infected population of suzhou, china".Virologica sinica 32.4(2017):271-279. |
入库方式： iSwitch采集
来源：武汉病毒研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。